BCA
HRTX icon

Berman Capital Advisors’s Heron Therapeutics HRTX Stock Holding History

Berman Capital Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$1K Buy
102
+33
+48% +$402 ﹤0.01% 1881
2021
Q2 		$1K Buy
+69
New +$1.1K ﹤0.01% 1747

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Berman Capital Advisors's HRTX Position: Q3 2021 in Review

Berman Capital Advisors increased its Heron Therapeutics (HRTX) stake by 48% in Q3 2021, buying an estimated $402 and bringing the position to 102 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #1881.

Berman Capital Advisors first reported a position in HRTX in Q2 2021 and has held it in 2 quarters since. 197 funds tracked by Wall St. Rank hold HRTX as of Q3 2021.

  • Berman Capital Advisors held 102 shares of Heron Therapeutics worth $1K as of Q3 2021.
  • Berman Capital Advisors bought 33 Heron Therapeutics shares in Q3 2021, an estimated $402.
  • Heron Therapeutics made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #1881 holding.
  • Berman Capital Advisors first reported a position in Heron Therapeutics in Q2 2021 and has held it in 2 quarters since.
  • 197 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.